APA (7th ed.) Citation

I, Z., N, L., P, G., TL, R., S, J., O, M., . . . F, L. (2022). Activation of CEACAM1 with an agonistic monoclonal antibody results in inhibition of melanoma cells. Cancer gene therapy, 29(11), 1676. https://doi.org/10.1038/s41417-022-00486-x

Chicago Style (17th ed.) Citation

I, Zaffran, Landolina N, Gaur P, Rovis TL, Jonjic S, Mandelboim O, Singer BB, and Levi-Schaffer F. "Activation of CEACAM1 with an Agonistic Monoclonal Antibody Results in Inhibition of Melanoma Cells." Cancer Gene Therapy 29, no. 11 (2022): 1676. https://doi.org/10.1038/s41417-022-00486-x.

MLA (9th ed.) Citation

I, Zaffran, et al. "Activation of CEACAM1 with an Agonistic Monoclonal Antibody Results in Inhibition of Melanoma Cells." Cancer Gene Therapy, vol. 29, no. 11, 2022, p. 1676, https://doi.org/10.1038/s41417-022-00486-x.